NCT03810976 is a Phase 2 clinical trial of Eribulin, gemcitabine in Sarcoma, sponsored by Yonsei University.

Who is sponsoring NCT03810976?

NCT03810976 is sponsored by Yonsei University.

What drugs are being tested in NCT03810976?

Interventions in NCT03810976: Eribulin, gemcitabine.

Is NCT03810976 still recruiting?

NCT03810976 is currently completed. Last updated 16 June 2022.

Last reviewed 2022-06-16 · How we verify

NCT03810976

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma

Completed Phase 2 Last updated 16 June 2022

What this trial tests

Phase 2 trial testing Eribulin, gemcitabine in Sarcoma in 37 participants. Completed in 30 May 2022.

Timeline

27 March 2018

Primary endpoint
30 May 2022

30 May 2022

Quick facts

Lead sponsor	Yonsei University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	27 March 2018
Primary completion	30 May 2022
Estimated completion	30 May 2022
Sites	1 location across South Korea

Drugs / interventions tested

Eribulin, gemcitabine — full drug profile →

Conditions studied

Sarcoma — all drugs for Sarcoma →

Sponsor

Yonsei University

Who can join

19 and older, any sex, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The eribulin, a microtubule-dynamics inhibitor was approved for specific subtypes of STS. Eribulin demonstrated significantly better OS compared to dacarbazine in previously treated patients with liposarcoma and leiomyosarcoma and approved as standard treatment. However, the median progression free survival (PFS) and response rate (RR) was similar for both groups which remains modest outcome of 2.6 months of PFS and 4% of RR. Therefore, to improve antitumor activity, further combination strategy is strongly warranted. Based on the previous studies, investigators suggest phase II trial of eribulin and gemcitabine combination in previously treated patients with unresectable, advanced, or metastatic leiomyosarcoma or liposarcoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Biomaterials from the sea: Future building blocks for biomedical applications.
Wan MC, Qin W, Lei C, Li QH, et al · · 2021 · cited 69× · PMID 33997505 · DOI 10.1016/j.bioactmat.2021.04.028
Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.
Giusti V, Miserocchi G, Sbanchi G, Pannella M, et al · · 2024 · cited 9× · PMID 39200384 · DOI 10.3390/biomedicines12081921
Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions.
Montella L, Altucci L, Sarno F, Buonerba C, et al · · 2021 · cited 6× · PMID 34068344 · DOI 10.3390/cancers13102359

Verify or expand the search:

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03810976 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 16 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03810976.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing